๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
Northwest Biotherapeutics, Inc. (NWBO)
OTCMKTS ยท Delayed Price ยท Currency is USD
0.1265
-0.0125 (-8.99%)
At close: Nov 20, 2026

Northwest Biotherapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
2.861.381.381.931.681.01
Revenue Growth
204.80%-0.29%-28.47%14.79%67.46%-22.15%
Gross Profit
-17.48-27.41-33.51-25.8-33.83-19.3
Operating Income
-45.95-59.91-66.51-55.51-67.18-52.7
Net Income
-40.71-61.48-85.19-64.37-105.03179.13
Earnings Per Share
-0.03-0.04-0.07-0.06-0.10-0.06
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.733.042.182.136.9715.17
Total Debt
69.8464.8367.4445.5626.2537.94
Net Cash (Debt)
-69.11-61.79-65.27-43.43-19.29-22.77
Net Cash Growth
------
Net Cash Per Share
-0.04-0.04-0.05-0.04-0.02-0.02

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-43.2-44.76-57.02-53.64-52.78-38.3
Capital Expenditures
-1.29-1.5-1.01-3.44-2.9-6.02
Free Cash Flow
-44.49-46.27-58.03-57.07-55.68-44.31
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Margin
-1608.82%-4347.90%-4812.45%-2873.09%-3991.74%-5243.98%
Pretax Margin
-1407.60%-4404.86%-6062.08%-3240.11%-6240.76%17823.48%
Profit Margin
-1425.45%-4461.32%-6164.40%-3331.94%-6240.76%17823.48%
FCF Margin
-1557.60%-3357.55%-4199.06%-2954.14%-3308.20%-4409.35%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
-----3.70
PS Ratio
79.03260.08263.35425.38493.23660.04